Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis
Tóm tắt
The safety of using heparin concomitantly with drotrecogin alfa (activated) {DrotAA} was explored in the XPRESS study. No heparin effect on mortality was observed. Safety results from that study are explored in more detail. A randomized, double-blind trial of prophylactic heparin versus placebo in severe sepsis patients treated with DrotAA (24 μg/(kg h) for 96 h) was conducted at 224 sites in 20 countries. Patients were randomized 1:1:2 to receive unfractionated heparin (UFH) (5,000 Units twice daily) (n = 511), low-molecular-weight heparin (LMWH) (enoxaparin, 40 mg per day) (n = 493), or placebo (n = 990) every 12 h during the DrotAA infusion. Bleeding events during the DrotAA infusion period (Days 0–6) were higher in the heparin than placebo groups (10.8 vs. 8.1%; p = 0.049), but serious bleeding events were similar (heparin 2.3% vs. placebo 2.5%; p = 0.72) and central nervous system (CNS) bleeds were rare in both groups (0.3 vs. 0.3%). Fewer heparin patients experienced an ischemic stroke during infusion (0.3 vs. 1.3%; p = 0.018) and 28-day period (0.5 vs. 1.8%; p = 0.009). Coadministration of DrotAA with low-dose heparin in severe sepsis patients did not increase incidence of serious bleeding. Fewer ischemic strokes in the heparin group suggest heparin cessation should be avoided during DrotAA infusion.
Tài liệu tham khảo
Bernard GR, Vincent JL, Laterre PF, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL (2007) Prophylactic heparin in patients with severe sepsis undergoing treatment with drotrecogin alfa (activated). Am J Resp Crit Care Med 176:43–90
Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ 5:338
Agresti A (1990) Categorical data analysis. Wiley, New York
Vincent J-L, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277
Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341
Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33:426–434
Vincent J-L, Laterre P-F, Decruyanaere J, Spapen H, Raemaekers J, Damas F, Rogiers P, Sartral M, Haentjens T, Nelson D, Janes J (2008) A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units—an observational studies. Acta Clin Belg 63:25–30
Rowan K, Welch C, North E, Harrison D (2008) Drotrecogin alfa (activated): real life use and outcomes for the UK. Crit Care 12:1–12
Kübler A, Mayzner-Zawadzka E, Durek G, Gaszyñski W, Karpel E, Mikaszewska Sokolewicz M, Majak P (2006) Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit 12:CR107–CR112
Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 33:517–523
LaMonte MP, Brown PM, Hursting MJ (2004) Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32:976–980
Arepally GM, Ortel TL (2006) Heparin-induced thrombocytopenia. N Engl J Med 355:809–817
Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB (1993) Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21:1039–1047
Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE (2005) Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 20:348–353
Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK (1999) Prospective study of markers of homeostatic function with risk of ischemic stroke. Circulation 100:736–743
Griffin JH, Fernandez JA, Liu D, Cheng T, Guo H, Zlokovic BV (2004) Activated protein C and ischemic stroke. Crit Care Med 32:S247–S253
Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM (2001) Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes. Observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 104:2772–2777
Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM (1995) Rebound increase in thrombin generation and activity after cessation of intravenous heparin patients with acute coronary syndromes. Circulation 91:1929–1935
Becker RC, Spencer FA, Li Y, Ball SP, Ma Y, Hurley T, Hebert J (1999) Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes. J Am Coll Cardiol 34:1020–1027
Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, Peters RJ (2002) Rebound thrombin generation after heparin therapy in unstable angina: a randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 39:811–817
Bijsterveld NR, Peters RJ, Murphy SA, Bernink PJ, Tijssen JG, Cohen M (2003) Recurrent cardiac ischemic events early after discontinuation of short term heparin treatment in acute coronary syndromes: results from TIMI IIB and ESSENCE studies. J Am Coll Cardiol 42:2083–2089
Di Nisio M, Bijsterveld NR, Meijers JC, Levi M, Büller HR, Peters RJ (2005) Effects of clopidrogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 46:1582–1583
Halkin H, Goldberg J, Mordan M, Modan B (1982) Reduction of mortality in general medical in-patients by low dose heparin prophylaxis. Ann Intern Med 96:561–565
Clagett GP, Reisch JS (1988) Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 208:227–240
Khouli H, Shapiro J, Pham VP, Arfaei A, Esan O, Jean R, Homel P (2006) Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit. J Intensive Care Med 21:352–358